Sachiyo Minegishi is the CFO, Treasurer, Assistant Sec. & Principal Accounting Officer at Akouos.
Ms Minegishi is 43, she's been the CFO, Treasurer a Assistant Sec. & Principal Accounting Officer of Akouos since . There are 3 older and 1 younger executives at Akouos. The oldest executive at Akouos, Inc. is Dr. Michael John McKenna M.D., 64, who is the Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board.
Sachiyo's mailing address filed with the SEC is C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON, MA, 02210.
Over the last 4 years, insiders at Akouos have traded over $16,920,000 worth of Akouos stock and bought 39,532,191 units worth $537,080,241 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Akouos executives and independent directors trade stock every 40 days with the average trade being worth of $24,448,882. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 30 November 2022, trading 29,992,668 units of AKUS stock currently worth $374,908,350.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Akouos executives and other stock owners filed with the SEC include: